5.12.2024 | Exploring China’s Healthcare Market – Trends, Opportunities, and Challenges
Webinar jointly organized by Healthtech Finland, Health Incubator Helsinki, and the Nordic Life Science Platform with the support of Business Finland.
Thursday, 5 December 2024 from 09.00 – 10.00 (Finland) / 15.00 – 16.00 (China)
Hear about the rapidly evolving Chinese healthcare market, how to navigate the China health opportunities, the fast-track entry policies at Hainan Boao Lecheng International Medical Tourism Pilot Zone (HBL) and Guangdong-Hong Kong-Macao Great Bay Area (GBA), and how to benefit from a Step-by-Step Market Entry Model.
Program and Agenda (Finland Time)
09:00-9:05 Welcome / Saara Hassinen, CEO, Healthtech Finland
09:05-9:15 Overview of the Chinese Healthcare Market / Noam David Stern, Co-founder & Director, Nordic Life Science Platform ApS
09:15-9:25 Navigating the China Health Opportunities / Sanorita Li, Head of Healthcare, Business Finland in China
09:25-09:40 Fast-track China Entry for Innovative Medical Products in China / Sharon Xu, Medical Project Manager, Nordic Life Science Platform ApS
09:40-09:50 Step-by-Step Market Entry Model to the Chinese Healthcare Market / Noam David Stern, Co-founder & Director, Nordic Life Science Platform ApS
09:50-10:00 Q&A and Closing Remarks / Christian Lardot, Incubator Lead – Senior Business Advisor, Health Incubator Helsinki
Who should participate?
Medtech, healthtech, pharma, and rehabilitation companies that are interested in exploring, entering or expanding their activities in the Chinese healthcare market, and seek practical advice and support from experienced China experts who can guide your company through the entire market entry process with HBL or GBA as possible stepping stones to the rest of mainland China.
Background
The development of the Chinese healthcare market is mainly driven by major demographic changes such as rising prosperity, increasing urbanization, falling birth rates and a rapidly aging population which is leading to a growing number of chronic diseases like cancer, diabetes, obesity, and mental health issues.
To satisfy the growing demand for high-quality healthcare services, China continues to invest massively in medical R&D, digitization, automation, tele-medicine, modern hospitals, advanced equipment, and new treatment methods.
At the same time, China is offering foreign companies with innovative medical products the opportunity for fast-track approvals for use at currently 28 leading hospitals in Hainan (HBL) and 45 in Guangdong (GBA).
Today, China is the world’s second largest market for both medical devices and drugs but despite the large market potential many Finnish companies still hold back from doing business in China due to lack of market knowledge and both real and perceived entry barriers and therefore consider it too difficult and risky.
To give Finnish companies a more safe, efficient, and easier access to the Chinese market, the Nordic Life Science Platform delivers a Step-by-Step Market Entry Model including matchmaking, expert advice and supporting services with the option to stop after each step before deciding their next move into China.
Lisätietoja
